1. Home
  2. KPTI vs VIGL Comparison

KPTI vs VIGL Comparison

Compare KPTI & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • VIGL
  • Stock Information
  • Founded
  • KPTI 2008
  • VIGL 2020
  • Country
  • KPTI United States
  • VIGL United States
  • Employees
  • KPTI N/A
  • VIGL N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • VIGL Health Care
  • Exchange
  • KPTI Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • KPTI 81.1M
  • VIGL 89.3M
  • IPO Year
  • KPTI 2013
  • VIGL 2022
  • Fundamental
  • Price
  • KPTI $0.63
  • VIGL $2.64
  • Analyst Decision
  • KPTI Strong Buy
  • VIGL Strong Buy
  • Analyst Count
  • KPTI 4
  • VIGL 5
  • Target Price
  • KPTI $5.00
  • VIGL $21.00
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • VIGL 2.6M
  • Earning Date
  • KPTI 02-27-2025
  • VIGL 03-25-2025
  • Dividend Yield
  • KPTI N/A
  • VIGL N/A
  • EPS Growth
  • KPTI N/A
  • VIGL N/A
  • EPS
  • KPTI N/A
  • VIGL N/A
  • Revenue
  • KPTI $148,442,000.00
  • VIGL N/A
  • Revenue This Year
  • KPTI $5.47
  • VIGL N/A
  • Revenue Next Year
  • KPTI $6.33
  • VIGL N/A
  • P/E Ratio
  • KPTI N/A
  • VIGL N/A
  • Revenue Growth
  • KPTI 1.77
  • VIGL N/A
  • 52 Week Low
  • KPTI $0.58
  • VIGL $1.49
  • 52 Week High
  • KPTI $1.70
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • VIGL 71.47
  • Support Level
  • KPTI $0.60
  • VIGL $2.22
  • Resistance Level
  • KPTI $0.70
  • VIGL $2.53
  • Average True Range (ATR)
  • KPTI 0.05
  • VIGL 0.29
  • MACD
  • KPTI -0.00
  • VIGL 0.08
  • Stochastic Oscillator
  • KPTI 46.61
  • VIGL 80.47

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: